Diaceutics and London Genetics are working together to develop software decision tools that will provide biopharmaceutical companies with access to academic biomarker research groups. The aim is to enable commercial biomarker research teams to comprehensively explore global biomarker resources to identify genes and gene sequences as well as the researchers and clinicians relevant to their targeted therapy research.
The new software, which is expected to launch in 2011, is based on the Diaceutics Fusion platform and the London Genetics Biomarker Pathway platform. The tools will allow research teams to build biomarker hypotheses, request expressions of interest, and prepare proposals for clinical development.
The expressions of interest, requesting access to patient samples and investigator networks, will be sent to academic biomarker research teams globally, including London Genetics' own network of over 3,000 investigators.
"We are delighted to partner with London Genetics, leverage their biomarker expertise, and together build tools that will address a key problem for therapy development teams," remarks Peter Keeling, CEO of Diaceutics. "Biomarker research is often limited because teams don't know the capabilities of external research centers and miss potential collaborations that could accelerate their targeted therapy development."
London Genetics is a not-for-profit company that was established in 2007 with funding from the London Development Agency. It leverages pharmacogenetics in clinical drug discovery and development. Recent agreements developed by London Genetics include a collaboration between the International Serious Adverse Events Consortium, St. George's University of London, and the Drug Safety Research Unit at Southampton, U.K.
Diaceutics is an international change-management and consulting firm specializing in personalized medicine. Its goal is to connect pharmaceutical and diagnostic companies and to provide the pharmaceutical industry with the foundation and operational structure necessary to effectively develop and commercialize targeted therapies that better meet patients' needs and improve return on investment.